Bio‑Rad Q1 Misses GAAP EPS, Shares Slip 1% After‑Hours on Weak Outlook

Earnings Snapshot

- GAAP EPS: $‑19.55 vs. $‑19.47 expected (miss $0.08)

- Non‑GAAP EPS: $1.89 vs. $1.97 expected (miss $0.08)

- Revenue: $592.1 M vs. $589.9 M consensus (beat $2.2 M)

- YoY Sales Growth: +1.1% (currency‑neutral decline of 4.2%)

- Gross Margin: 52.3% (flat YoY)

- Operating Cash Flow: $108.1 M; Free Cash Flow: $78.1 M

- Share Repurchase: ~176 k shares repurchased in the quarter.

Why the Stock Fell

The market reaction was driven less by the modest revenue beat and more by the GAAP loss and a markedly weaker FY‑2026 outlook.

- Guidance downgrade: Bio‑Rad now expects non‑GAAP, currency‑neutral revenue to decline up to 3% or grow as little as 0.5%—a shift from the prior 0.5%‑1.5% growth range.

- Operating margin outlook: Projected non‑GAAP operating margin of 10%‑12% versus the earlier 12%‑12.5% range, signaling tighter profitability.

- Analyst sentiment: MarketBeat and Morningstar notes highlighted that the outlook “raises concerns about near‑term earnings momentum,” prompting several analysts to trim price targets. One note described the after‑hours move as “a modest sell‑off reflecting disappointment in the GAAP loss and the cautious FY guidance.”

CEO & Management Commentary

Norman Schwartz, Chairman and CEO, said the quarter “reflected our resolve in navigating a dynamic environment.” He pointed to:

- External headwinds: Ongoing challenges in the academic research market (especially in the Americas) and the escalation of regional conflicts in the Middle East, which weighed on the Clinical Diagnostics segment.

- Cash generation: $78 M of free cash flow and a $176 k share repurchase program, underscoring the company’s financial strength.

- Operational focus: Continued evaluation and optimization of the organization to create more value for customers and shareholders.

Conference Call Highlights

Key takeaways from the 5 p.m. ET earnings call included:

- Segment performance: Life Science sales were essentially flat at $228.5 M (‑4.3% currency‑neutral), while Clinical Diagnostics grew 1.9% to $363.6 M (‑4.1% currency‑neutral).

- Equity investment impact: A fair‑value adjustment on the company’s stake in Sartorius AG drove a $527 M GAAP net loss, a non‑recurring item that analysts said should be viewed separately from operating performance.

- Outlook confidence: Management reaffirmed its belief in the long‑term durability of the business, citing strong cash flow and a disciplined capital allocation strategy.

Market Context & Peer Comparison

Bio‑Rad’s modest after‑hours dip contrasts with a broader life‑science sector that saw mixed results this week. Peers such as Thermo Fisher and Agilent posted stronger top‑line growth, putting additional pressure on Bio‑Rad’s relative valuation. The 1% pullback also aligns with the modest sell‑off noted by ChartMill for prior quarters, suggesting the market remains sensitive to any guidance softening.

What’s Next?

Investors will watch the upcoming Q2 results for signs that the company can stabilize margins and offset the academic‑research slowdown. The revised FY outlook implies a tighter earnings runway, making the company’s cash‑generation capability and share‑repurchase program key metrics to monitor.

---

All figures are from Bio‑Rad’s Q1 2026 8‑K filing and after‑hours market data as of 5:43 p.m. ET.